CZ Vaccines secures healthy growth in 2019

Spanish firm CZ Vaccines has posted a 4% improvement in annual sales during 2019.

While the company is a leading supplier of bluetongue vaccines, 2019 was largely boosted by sales of two other product lines. Revenues from vaccines for clostridial diseases went up by 21% in 2019, while sales of the firm’s Gudair Johne’s disease vaccine climbed 21.5%.

CZ claims to be the top European manufacturer in the field of clostridial vaccines, which it distributes across Europe, Africa, Australia and Latin America. The company said Gudair is the only Johne’s vaccine to provide lifelong immunity to small ruminants with one dose.
The Porriño-based business has recorded a 20% improvement in sales since 2015 – growth that has strengthened the firm’s position as “one of the leading companies” focused on mycobacteria, clostridial, bacterial and zoonotic disease vaccines.
The company expects more growth ahead in fiscal 2020. CZ told Animal Pharm it expects increased sales in Russia, Turkey and Canada over the coming year. In terms of products, the firm expects its mycobacterium and bacterial vaccines to stimulate growth.
As well as manufacturing veterinary vaccines, CZ provides contract development and manufacturing services for biological products. It has a commercial presence in around 65 countries.
In 2019, CZ partnered with Ireland’s Marinnovac to establish an aquaculture vaccine business. Last year also saw CZ introduce a new conjunctival vaccine against brucellosis.